Serum CA19-9 Response As a Surrogate for Clinical Outcome in Patients Receiving Fixed-dose Rate Gemcitabine for Advanced Pancreatic Cancer

Overview

Journal Br J Cancer

Specialty Oncology

Date 2005 Jul 7

PMID 15999098

Citations 58

Authors

A H Ko

J Hwang

A P Venook

J L Abbruzzese

E K Bergsland

M A Tempero

Affiliations

Soon will be listed here.

Abstract

The use of serial serum measurements of the carbohydrate antigen 19-9 (CA19-9) to guide treatment decisions and serve as a surrogate end point in clinical trial design requires further validation. We investigated whether CA19-9 decline represents an accurate surrogate for survival and time to treatment failure (TTF) in a cohort of 76 patients with advanced pancreatic cancer receiving fixed-dose rate gemcitabine in three separate studies. Statistically significant correlations between percentage CA19-9 decline and both overall survival and TTF were found, with median survival ranging from 12.0 months for patients with the greatest degree of biomarker decline (> 75%) compared with 4.3 months in those whose CA19-9 did not decline during therapy (P < 0.001). Using specific thresholds, patients with > or = 25% decline in CA19-9 during treatment had significantly better outcomes than those who did not (median survival and TTF of 9.6 and 4.6 months vs 4.4 and 1.5 months; P < 0.001). Similar results were seen using both 50 and 75% as cutoff points. We conclude that serial CA19-9 measurements correlate well with clinical outcomes in this patient population, and that decline in this biomarker should be entertained for possible use as a surrogate end point in clinical trials for the selection of new treatments in this disease.

Citing Articles

New-onset diabetes is a predictive risk factor for pancreatic lesions in high-risk individuals: An observational cohort study.

Baydogan S, Mohindroo C, Hasanov M, Montiel M, Quesada P, Cazacu I Endosc Ultrasound. 2024; 13(2):83-88.

PMID: 38947744 PMC: 11213578. DOI: 10.1097/eus.0000000000000057.

Clinical practice guidelines for molecular tumor marker, 2nd edition review part 2.

Kikuchi Y, Shimada H, Yamasaki F, Yamashita T, Araki K, Horimoto K Int J Clin Oncol. 2024; 29(5):512-534.

PMID: 38493447 DOI: 10.1007/s10147-024-02497-0.

[F] AlF-NOTA-FAPI-04 PET/CT can predict treatment response and survival in patients receiving chemotherapy for inoperable pancreatic ductal adenocarcinoma.

Zhu Z, Cheng K, Yun Z, Zhang X, Hu X, Liu J Eur J Nucl Med Mol Imaging. 2023; 50(11):3425-3438.

PMID: 37328622 DOI: 10.1007/s00259-023-06271-8.

Utility of endoscopic ultrasound for assessment of locoregional recurrence of pancreatic adenocarcinoma after surgical resection.

Ragheb J, Simons-Linares C, Pluskota C, Confer B, Butler R, Diehl D Endosc Int Open. 2023; 11(4):E401-E408.

PMID: 37102183 PMC: 10125777. DOI: 10.1055/a-2046-4984.

Results of a single-arm pilot study of P microparticles in unresectable locally advanced pancreatic adenocarcinoma with gemcitabine/nab-paclitaxel or FOLFIRINOX chemotherapy.

Ross P, Wasan H, Croagh D, Nikfarjam M, Nguyen N, Aghmesheh M ESMO Open. 2021; 7(1):100356.

PMID: 34953400 PMC: 8717429. DOI: 10.1016/j.esmoop.2021.100356.

References

Halm U, Schumann T, Schiefke I, Witzigmann H, Mossner J, Keim V . Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer. 2000; 82(5):1013-6. PMC: 2374423. DOI: 10.1054/bjoc.1999.1035. View

Jemal A, Murray T, Ward E, Samuels A, Tiwari R, Ghafoor A . Cancer statistics, 2005. CA Cancer J Clin. 2005; 55(1):10-30. DOI: 10.3322/canjclin.55.1.10. View

Saad E, Machado M, Wajsbrot D, Abramoff R, Hoff P, Tabacof J . Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine. Int J Gastrointest Cancer. 2003; 32(1):35-41. DOI: 10.1385/IJGC:32:1:35. View

Micke O, Bruns F, Schafer U, Kurowski R, Horst E, Willich N . CA 19-9 in the therapy monitoring and follow-up of locally advanced cancer of the exocrine pancreas treated with radiochemotherapy. Anticancer Res. 2003; 23(2A):835-40. View

Micke O, Bruns F, Kurowski R, Horst E, DeVries A, Hausler J . Predictive value of carbohydrate antigen 19-9 in pancreatic cancer treated with radiochemotherapy. Int J Radiat Oncol Biol Phys. 2003; 57(1):90-7. DOI: 10.1016/s0360-3016(03)00524-8. View

Tempero M, Plunkett W, Ruiz Van Haperen V, Hainsworth J, Hochster H, Lenzi R . Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol. 2003; 21(18):3402-8. DOI: 10.1200/JCO.2003.09.140. View

Ziske C, Schlie C, Gorschluter M, Glasmacher A, Mey U, Strehl J . Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Br J Cancer. 2003; 89(8):1413-7. PMC: 2394360. DOI: 10.1038/sj.bjc.6601263. View

Stemmler J, Stieber P, Szymala A, Schalhorn A, Schermuly M, Wilkowski R . Are serial CA 19-9 kinetics helpful in predicting survival in patients with advanced or metastatic pancreatic cancer treated with gemcitabine and cisplatin?. Onkologie. 2003; 26(5):462-7. DOI: 10.1159/000072980. View

KOPROWSKI H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fuhrer P . Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet. 1979; 5(6):957-71. DOI: 10.1007/BF01542654. View

10.

KOPROWSKI H, Herlyn M, Steplewski Z, Sears H . Specific antigen in serum of patients with colon carcinoma. Science. 1981; 212(4490):53-5. DOI: 10.1126/science.6163212. View

11.

Del Villano B, Brennan S, Brock P, Bucher C, Liu V, McClure M . Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9. Clin Chem. 1983; 29(3):549-52. View

12.

Steinberg W . The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol. 1990; 85(4):350-5. View

13.

Grunewald R, Kantarjian H, Keating M, Abbruzzese J, Tarassoff P, Plunkett W . Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia. Cancer Res. 1990; 50(21):6823-6. View

14.

Rothenberg M, Abbruzzese J, Moore M, Portenoy R, Robertson J, Wanebo H . A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma. Cancer. 1996; 78(3 Suppl):627-32. DOI: 10.1002/(SICI)1097-0142(19960801)78:3<627::AID-CNCR43>3.0.CO;2-Y. View

15.

Katz A, Hanlon A, Lanciano R, Hoffman J, Coia L . Prognostic value of CA 19-9 levels in patients with carcinoma of the pancreas treated with radiotherapy. Int J Radiat Oncol Biol Phys. 1998; 41(2):393-6. DOI: 10.1016/s0360-3016(98)00058-3. View

16.

Okusaka T, Okada S, Sato T, Wakasugi H, Saisho H, Furuse J . Tumor markers in evaluating the response to radiotherapy in unresectable pancreatic cancer. Hepatogastroenterology. 1998; 45(21):867-72. View

17.

Ikeda M, Okada S, Tokuuye K, Ueno H, Okusaka T . Prognostic factors in patients with locally advanced pancreatic carcinoma receiving chemoradiotherapy. Cancer. 2001; 91(3):490-5. DOI: 10.1002/1097-0142(20010201)91:3<490::aid-cncr1027>3.0.co;2-l. View